Investing.com — U.S. stocks mostly rose Friday, with the Nasdaq and S&P 500 set to end the week higher, despite some investor caution.
Here are Investing.com’s stocks of the week:
While the list this week is heavily earnings-related, the first name surged for a different reason.
MASI shares jumped over 34% on Tuesday on news that Danaher Corporation has entered into an agreement to acquire Masimo for $180 per share in cash, representing a total enterprise value of approximately $9.9 billion, including assumed indebtedness and net of acquired cash.
Meanwhile, RingCentral has jumped by more than 32% so far on Friday, putting its stock around 36% higher in the last week after its latest earnings release impressed investors.
RNG reported Q4 EPS of $1.18, $0.04 better than the analyst estimate of $1.14, while revenue for the quarter came in at $644 million versus the consensus estimate of $643.61 million.
“RNG delivered solid Q4 results,” said Morgan Stanley analyst Siti Panigrahi in a reaction note. “While RNG continues to innovate and launch new products to drive future growth, it’s also transitioning its financial model to reflect the current growth profile.”
GPN was another earnings winner, with its stock rallying by more than 16% on Wednesday. A further 2% climb on Friday so far has pushed the shares to around $81.83 apiece, up 18% in the last week.
The company reported fourth-quarter EPS of $3.18, $0.02 above the analyst estimate of $3.16, and revenue of $2.32 billion, in line with the consensus estimate. Looking ahead, the company expects adjusted earnings per share of $13.80 to $14.00 in 2026, representing 13% to 15% growth and beating consensus estimates of $13.78.
On the downside, Klarna shares plunged over 26% on Thursday in reaction it ts latest quarterly release. The stock has declined a further 5.3% so far on Friday.
Klarna reported revenue for the quarter of $1.08 billion, versus the consensus estimate of $1.07 billion.
However, Compass Point analyst Dominick Gabriele said “4Q25 was a miss up and down the P&L.”
“Heading into 2026, we grew incrementally cautious on KLAR and today’s earnings call doesn’t increase our confidence level NT,” he added. “We only maintain a BUY rating due to our call that in the 2H26 KLAR’s stock is likely to bounce back. The 2026 outlook is also underwhelming vs. our expectations as funding costs are much higher than we expected, putting some pressure on adjusted operating income margin.”
Avis Budget, which already had significant short interest and had fallen sharply since August 2025, saw its stock decline further on Thursday, down around 21.5% in response to its quarterly report.
The company reported a Q4 loss per share of $21.25, while revenue for the quarter came in at $2.7 billion, below the consensus estimate of $2.75 billion.
The company’s shares now trade well below the $100 mark at around $95.95.
Finally, Grail plummeted 49.7% on Friday despite posting a narrower-than-expected quarterly loss, with investors instead focusing on the biotech firm’s flagship NHS-Galleri trial, which failed to meet its primary clinical endpoint of a statistically significant reduction in combined Stage III and IV cancer diagnoses.
TD Cowen analyst Dan Brennan said the study failure is a “major setback” for the company.
“Our prior work felt this would be negative for key catalysts (FDA, Medicare),” wrote the analyst. “On the contrary, management was positive noting favorable trial data signals supporting Galleri’s utility & are confident in FDA approval.”
Related articles
Investing.com’s stocks of the week
These 2 stocks are best positioned to benefit from higher uranium prices: analyst
Morgan Stanley CIO survey: Why AI hype isn’t boosting 2026 IT budgets